WHO Approves First Monkeypox Vaccine
- Hidden Perils After COVID-19: A Surge in Dementia and Mental Disorders
- Clozapine Tied to Higher Risk of GI Issues and Pneumonia
- Cassava Sciences Faces $40 Million Fine Over Alleged Fraud in Alzheimer’s Drug Trials
- Can Cytokine Modulation Enhance the Efficacy of CAR-T Cell Therapy?
- What Are HIV-Related Cancers and How Can They Be Prevented?
- Metformin: From Diabetes Treatment to a New Approach for HIV Cure
WHO Approves First Monkeypox Vaccine
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
WHO Approves First Monkeypox Vaccine
On September 13, the World Health Organization (WHO) announced the emergency use authorization for the first monkeypox vaccine, developed by Denmark-based Bavarian Nordic.
This is the first vaccine approved by WHO for combating the monkeypox outbreak.
WHO Director-General Tedros Adhanom Ghebreyesus stated, “The prequalification of the monkeypox vaccine marks a significant step in our fight against this disease, both for the ongoing outbreak in Africa and potential future outbreaks.”
Following the approval, individuals aged 18 and above can receive two doses of the vaccine, spaced four weeks apart. Given that most confirmed and fatal cases of monkeypox in the Democratic Republic of Congo (DRC) involve minors, WHO has stated that this vaccine can also be administered to infants, children, adolescents, pregnant women, and immunocompromised individuals.
On August 14, WHO declared the monkeypox outbreak a “Public Health Emergency of International Concern.” According to WHO, a new strain of the monkeypox virus, “clade Ib,” emerged in the DRC last year and has since spread rapidly to countries including Burundi, Kenya, Rwanda, and Uganda.
Since January this year, the DRC has reported nearly 22,000 confirmed cases and 716 deaths. The country is set to begin the first round of vaccinations in early October.
According to Reuters, the monkeypox vaccine produced by Bavarian Nordic was originally intended to prevent smallpox infection and has already been used in the United States to prevent monkeypox. WHO Emergency Committee Chair Dimi Ogoina previously stated that “current evidence suggests that this vaccine provides significant protection,” but emphasized that it is not a “silver bullet” and that other public health measures, such as testing and contact tracing, remain essential.
Bavarian Nordic has previously announced plans to supply 13 million doses of the monkeypox vaccine by the end of 2025.
Meanwhile, the monkeypox vaccine developed by Japan’s KM Biotech is still under evaluation by WHO.
Monkeypox is a viral zoonotic disease. Early symptoms in humans include fever, headache, muscle aches, back pain, and swollen lymph nodes, followed by a widespread rash on the face and body. While most infected individuals recover within a few weeks, some may experience severe illness or even death.
WHO Approves First Monkeypox Vaccine
—————
(source:internet, reference only)(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
